Maybe it's the rarefied Davos air or the long-range mountain views, but Novartis ($NVS) CEO Joe Jimenez is feeling optimistic about the post- Diovan future. After the Swiss drugmaker loses patent...
The National Institute for Health and Clinical Excellence has struck again. Despite two appeals of its draft recommendations, the agency let in only one new drug for chronic myeloid leukemia.
The U.K.'s cost-effectiveness watchdog rejected Bristol-Myers Squibb's ($BMY) Sprycel for chronic myeloid leukemia, but accepted Novartis' ($NVS) Glivec and its follow-up drug Tasigna after the Swiss
The National Institute for Health and Clinical Excellence has taken Novartis ($NVS) up on its offer of a discount on Tasigna. The cost-effectiveness watchdog gave Tasigna a preliminary thumbs-up as a
With cancer drugs, the first approval is only the beginning. An indication for one type of cancer can become two or three if drugmakers play their cards right--and if the treatments themselves prove
Tasigna continues to surpass Glivec as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, according to a statement issued
Novartis' Tasigna won its first European approval as a first-line treatment when Swiss authorities green-lighted the blood cancer drug after a fast-track review. Novartis release | Report
More evidence that social media is a potential minefield for drugmakers, at least until FDA finally makes up new rules. The agency's DDMAC division has cited Novartis for a Facebook widget on its
Novartis has taken one step closer to making its cancer drug Tasigna a robust successor to its blockbuster treatment Gleevec. The FDA gave its blessing to Tasigna as a first-line treatment for a rare
What does a drugmaker do when a huge drug is edging toward that patent cliff? It pushes another branded med as a replacement for that soon-to-go-generic treatment--and crosses its fingers in hopes